Adjunctive treatment of myxopapillary ependymoma

Amin Jahanbakhshi; Masoumeh Najafi; Fatemeh Jafari; Mahsa Moshtaghian; Marzieh Gomar; Mousareza Anbarlouei; Soheil Naderi

doi:10.4081/oncol.2021.518

https://doi.org/10.4081/oncol.2021.518

Amin Jahanbakhshi Skull Base Research Center, Neurosurgery Department, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Masoumeh Najafi Skull Base Research Center, Neurosurgery Department, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Fatemeh Jafari | fatemeh.jafari92@yahoo.com Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran; Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Mahsa Moshtaghian Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran; Department of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Marzieh Gomar Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Mousareza Anbarlouei Neurosurgery Department, Baqiyatallah University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Soheil Naderi Neurosurgery Department, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of.

Abstract

Myxopapillary ependymoma are rare tumors and optimal therapeutic strategy is remained controversial. The main treatments for myxopapillary ependymoma tumors include surgery and radiotherapy. Hence, the present study aimed to review adjuvant treatment of myxopapillary ependymoma, focusing on spinal myxopapillary ependymoma. The information sources of all articles were the English authoritative databases including PubMed, Web of science, Scopus, Science direct and Google scholar. In this review study, the keywords including adjuvant, treatment, myxopapillary and ependymoma were selected from MeSH medical library. Related articles were published from 2000 to 2020. Given radiation tolerance in the spinal cord is 10-15% lower than that of the brain, it also should be noted that with increased dose and scope of therapeutic field, the corresponding risks are increased, as well. Also, chemotherapy has never been used as the primary treatment approach. Radiotherapy’s value is considered while involving with sensitive areas where chemotherapy is also recommended. Gross total resection is the preferred primary treatment. But the role of adjuvant radiotherapy is debated in different tumor and patient scenarios and no standard treatment strategy had been defined yet. The bottom line is that as long as cellular and molecular methods or gene therapy can be used in the treatment of myxopapillary ependymoma, all the studies confirm that the best treatment method is still wide surgical resection as much as possible.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Al‐Halabi H, Montes JL, Atkinson J, et al. Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas. Pediat Blood Cancer 2010;55:639-43. DOI: https://doi.org/10.1002/pbc.22614

Agbahiwe HC, Wharam M, Batra S, et al. Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Physics 2013;85:421-7. DOI: https://doi.org/10.1016/j.ijrobp.2012.05.001

van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiat 1996;61:321-3. DOI: https://doi.org/10.1136/jnnp.61.3.321

Lemjabbar-Alaoui H, Hassan OU, Yang Y-W, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta Rev Cancer 2015;185:189-210. DOI: https://doi.org/10.1016/j.bbcan.2015.08.002

Herholz K, Langen K-J, Schiepers C, Mountz JM. Brain tumors. vol 6. In: Seminars in nuclear medicine. Amsterdam: Elsevier; 2012. pp 356-370. DOI: https://doi.org/10.1053/j.semnuclmed.2012.06.001

Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953-68. DOI: https://doi.org/10.1002/cncr.23741

Saponara M, Pantaleo MA, Nannini M, Biasco G. Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncol 2014;10:2045-59. DOI: https://doi.org/10.2217/fon.14.109

Zadnik PL, Gokaslan ZL, Burger PC, Bettegowda C. Spinal cord tumours: advances in genetics and their implications for treatment. Nature Rev Neurol 2013;9:257. DOI: https://doi.org/10.1038/nrneurol.2013.48

Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015;27:728-43. DOI: https://doi.org/10.1016/j.ccell.2015.04.002

De Jong L, Van Calenbergh F, Menten J, et al. Ependymomas of the filum terminale: The role of surgery and radiotherapy. Surg Neurol Int 2012;3:76. DOI: https://doi.org/10.4103/2152-7806.98509

Lee S-H, Chung CK, Kim CH, et al. Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group. Neuro-oncol 2013;15:921-9. DOI: https://doi.org/10.1093/neuonc/not038

Freyschlag C, Tuettenberg J, Lohr F, et al. Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. Anticancer Res 2011;3:1023-5.

Tsai CJ, Wang Y, Allen PK, et al. Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. Neurosurgery 2014;75 :205-14. DOI: https://doi.org/10.1227/NEU.0000000000000408

Liu T, Yang C, Deng X, et al. Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas. Neurosurg Rev 2019:1-6.

Bates JE, Choi G, Milano MT. Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. J Neuro-Oncol 2016;129:251-8. DOI: https://doi.org/10.1007/s11060-016-2167-0

Wiestler OD, Schiffer D, Coons SW. Myxopapillary ependymoma. In: Kleihues P, Cavenee WK, eds. Pathology and genetics

of tumours of the central nervous system. Lyon: IARC; 2000. pp 78-79.

Barton VN, Donson AM, Kleinschmidt‐DeMasters BK, et al. Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathology 2010;20:560-70. DOI: https://doi.org/10.1111/j.1750-3639.2009.00333.x

Garvin Jr JH, Selch MT, Holmes E, et al. Phase II study of pre‐irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: A report from the Children's Oncology Group. Pediat Blood Cancer 2012;59:1183-9. DOI: https://doi.org/10.1002/pbc.24274

Venkatramani R, Ji L, Lasky J, et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neuro-oncol 2013;113:285-91. DOI: https://doi.org/10.1007/s11060-013-1111-9

Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017;133:5-12. DOI: https://doi.org/10.1007/s00401-016-1643-0

Kraetzig T, McLaughlin L, Bilsky MH, Laufer I. Metastases of spinal myxopapillary ependymoma: unique characteristics and clinical management. J Neurosurg Spine 2018;28:201-8. DOI: https://doi.org/10.3171/2017.5.SPINE161164

Rege SV, Narayan S, Patil H, Songara A. Spinal myxopapillary ependymoma with interval drop metastasis presenting as cauda equina syndrome: case report and review of literature. J Spine Surg 2016;2:216. DOI: https://doi.org/10.21037/jss.2016.08.06

Rezai AR, Woo HH, Lee M, et al. Disseminated ependymomas of the central nervous system. J Neurosurg 1996;85:618-24. DOI: https://doi.org/10.3171/jns.1996.85.4.0618

Cimino PJ, Agarwal A, Dehner LP. Myxopapillary ependymoma in children: a study of 11 cases and a comparison with the adult experience. Pediat Blood Cancer 2014;61:1969-71. DOI: https://doi.org/10.1002/pbc.25125

Abdallah A, Emel E, Gündüz HB, et al. Long-term surgical resection outcomes of pediatric myxopapillary ependymoma: experience of two centers and brief literature review. World

Neurosurg 2020;136:e245-61.

Pesce A, Palmieri M, Armocida D, et al. Spinal myxopapillary ependymoma: the sapienza university experience and comprehensive literature review concerning the clinical course of 1602 patients. World Neurosurg 2019;129:245-53. DOI: https://doi.org/10.1016/j.wneu.2019.05.206

Kaner T, Sasani M, Oktenoglu T, et al. Clinical analysis of 21 cases of spinal cord ependymoma: positive clinical results of gross total resection. J Korean Neurosurg Soc 2010;47:102. DOI: https://doi.org/10.3340/jkns.2010.47.2.102

Deletis V, Seidel K, Sala F, et al. Intraoperative identification of the corticospinal tract and dorsal column of the spinal cord by electrical stimulation. J Neurol Neurosurg Psychiat 2018;89:754-61. DOI: https://doi.org/10.1136/jnnp-2017-317172

Hussain I, Parker WE, Barzilai O, Bilsky MH. Surgical management of intramedullary spinal cord tumors. Neurosurg Clin 2020 [Epub ahead of print]. DOI: https://doi.org/10.1016/j.nec.2019.12.004

Akyurek S, Chang EL, Yu T-K, et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at MD Anderson Cancer Center. J Neuro-oncol 2006;80:177-83. DOI: https://doi.org/10.1007/s11060-006-9169-2

Rutz HP, Goitein G.In regard to the radiotherapy of myxopapillary ependymomas. Int J Radiat Oncol Biol Physics 2002;53:787. DOI: https://doi.org/10.1016/S0360-3016(02)02776-1

Haddad P, Miraie M, Farhan F, et al.Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI‐defined T3, T4 or N+ rectal cancer: a randomized clinical trial. Asia‐Pacif J Clin Oncol 2017;13:416-22. DOI: https://doi.org/10.1111/ajco.12675

Haddad P, Cheung F, Pond G, et al. Computerized tomographic simulation compared with clinical mark-up in palliative radiotherapy: a prospective study. Int J Radiat Oncol Biol Physics 2006;65:824-9. DOI: https://doi.org/10.1016/j.ijrobp.2006.01.034

Fassett DR, Pingree J, Kestle JR. The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients: report of five cases and review of the literature. J Neurosurg Pediat 2005;102:59-64. DOI: https://doi.org/10.3171/ped.2005.102.1.0059

Chinn DM, Donaldson SS, Dahl GV, et al. Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation. Med Pediat Oncol 2000;35:443-5. DOI: https://doi.org/10.1002/1096-911X(20001001)35:4<443::AID-MPO13>3.0.CO;2-3

Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro-oncol 2016;18:902-13. DOI: https://doi.org/10.1093/neuonc/now016

Pica A, Miller R, Villà S, et al. The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network. Int J Radiat Oncol Biol Physics 2009;74:1114-20. DOI: https://doi.org/10.1016/j.ijrobp.2008.09.034

Abdulaziz M, Mallory GW, Bydon M, et al. Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. Neurosurg Focus 2015;39:E8. DOI: https://doi.org/10.3171/2015.5.FOCUS15164

Pędziwiatr K, Skowrońska-Gardas A, Chojnacka M. Spinal cord ependymoma in children-Results of postoperative radiotherapy. Radiother Oncol 2013;106:181-5. DOI: https://doi.org/10.1016/j.radonc.2013.02.007

Lucchesi KM, Grant R, Kahle KT, et al. rimary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. J Neuro-oncol 2016;130:133-40. DOI: https://doi.org/10.1007/s11060-016-2218-6

Liu APY, Shing MMK, Yuen HL, et al. Timing of adjuvant radiotherapy and treatment outcome in childhood ependymoma. Pediat Blood Cancer 2014;61:606-11. DOI: https://doi.org/10.1002/pbc.24820

Tsao M, Sultanem K, Chiu D, et al. Supportive care management of brain metastases: What is known and what we need to know: Conference proceedings of the National Cancer Institute of Canada (NCIC) Workshop on Symptom Control in Radiation Oncology. Clin Oncol 2003;15:429-34. DOI: https://doi.org/10.1016/S0936-6555(03)00220-6

Millar B-AM, Purdie TG, Yeung I, et al. Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases. J Neuro-oncol 2005;71:281-6. DOI: https://doi.org/10.1007/s11060-004-1722-2

Schiopu S, Habl G, Häfner M, et al. Craniospinal irradiation using helical tomotherapy for central nervous system tumors. J Radiat Res 2017;58. doi:10.1093/jrr/rrw095 DOI: https://doi.org/10.1093/jrr/rrw095

Fujiwara Y, Manabe H, Izumi B, et al. Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. Eur Spine J 2018;27:421-5. DOI: https://doi.org/10.1007/s00586-017-5413-z

Deniel A, Marguet F, Beaussire L, et al. TERTp mutation detection in plasma by droplet-digital polymerase chain reaction in spinal myxopapillary ependymoma with lung metastases. World Neurosurg 2019;130:405-9. DOI: https://doi.org/10.1016/j.wneu.2019.07.111